Petros Pharmaceuticals, Inc.
PTPI· OTC
PTPIPetros Pharmaceuticals, Inc.
Quarterly figures for Petros Pharmaceuticals, Inc., with source filings when available.
22 quarters. Sep 30, 2020 to Jun 30, 2026. USD.
Petros Pharmaceuticals, Inc. has filed its 10-Q within 43 to 45 days of period end across its last 8 quarters. The 10-K runs 90 to 105 days.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | |||||||||
| Q2 2026 | Jun 30, 2026 | — | Aug 13, 2026 | 44 d | 10-Q | — | — | -$0.30 | |
| Mar 31, 2026 |
| — |
| May 13, 2026 |
| 43 d |
| 10-Q |
| — |
| — |
| -$0.03 |
| FY 2025 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2025derived | Dec 31, 2025 | — | Apr 15, 2026 | 105 d | 10-K | — | — | — | |
| Q3 2025 | Sep 30, 2025 | — | Nov 13, 2025 | 44 d | 10-Q | — | — | -$0.03 | |
| Q2 2025 | Jun 30, 2025 | — | Aug 14, 2025 | 45 d | 10-Q | — | — | -$1.20 | |
| Q1 2025 | Mar 31, 2025 | — | May 15, 2025 | 45 d | 10-Q | — | — | -$9.37 | |
| FY 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | — | Mar 31, 2025 | 90 d | 10-K | $725.40K | — | — | |
| Q3 2024 | Sep 30, 2024 | — | Nov 13, 2024 | 44 d | 10-Q | $1.58M | −5.9% | -$16.65 | |
| Q2 2024 | Jun 30, 2024 | — | Aug 14, 2024 | 45 d | 10-Q | $1.42M | −28.7% | -$9.25 | |
| Q1 2024 | Mar 31, 2024 | — | May 15, 2024 | 45 d | 10-Q | $1.39M | −44.8% | -$42.19 | |
| FY 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | — | Apr 1, 2024 | 92 d | 10-K | — | — | — | |
| Q3 2023 | Sep 30, 2023 | — | Nov 15, 2023 | 46 d | 10-Q | $1.67M | — | -$2.85 | |
| Q2 2023 | Jun 30, 2023 | — | Aug 14, 2023 | 45 d | 10-Q | $1.99M | −52.4% | -$1.20 | |
| Q1 2023 | Mar 31, 2023 | — | May 15, 2023 | 45 d | 10-Q | $2.52M | +2.1% | -$0.66 | |
| FY 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2022derived | Dec 31, 2022 | — | Mar 31, 2023 | 90 d | 10-K | $798.10K | — | — | |
| Q3 2022 | Sep 30, 2022 | — | Nov 14, 2022 | 45 d | 10-Q | — | — | -$6.69 | |
| Q2 2022 | Jun 30, 2022 | — | Aug 12, 2022 | 43 d | 10-Q | $4.19M | — | -$0.88 | |
| Q1 2022 | Mar 31, 2022 | Apr 4, 2022 · after-hours | May 16, 2022 | 46 d | 10-Q | $2.47M | — | -$0.08 | |
| FY 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2021derived | Dec 31, 2021 | — | Mar 31, 2022 | 90 d | 10-K | — | — | — | |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 · after-hours | Nov 15, 2021 | 46 d | 10-Q | $2.15M | −38.1% | -$0.17 | |
| FY 2020 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2020derived | Dec 31, 2020 | — | Mar 31, 2021 | 90 d | 10-K | $2.93M | — | — | |
| Q3 2020 | Sep 30, 2020 | — | — | — | — | $3.46M | — | -$0.96 | |
